HOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments ...

Three-phase, 36-month award aims to extend BrainEx perfusion from 24 hours to up to two weeks, enabling longitudinal studies of human brain biology and therapeutic responses - NEW HAVEN, Conn., Oct.

A Personal View published in The Lancet Oncology challenges the long-standing perception of metastatic brain cancer, calling to recognize it as a distinct central nervous system (CNS) disease rather ...

NEW HAVEN, Conn., June 10, 2025 (GLOBE NEWSWIRE) -- Bexorg, Inc., a pioneering techbio company working to decode the human brain and advance new therapies for central nervous system (CNS) disorders, ...

Sage Therapeutics has been working in the area of steroid-derived compounds that affect CNS receptor signaling. A pivotal trial failed to show benefit, and they had several other clinical failures as ...

LONDON--(BUSINESS WIRE)--Kesmalea Therapeutics, a biopharmaceutical company developing a pipeline of novel therapeutics founded on the ability to transform large protein degraders into small molecules ...